title: CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas.
abstract: Gastric cancer (GC) is a highly aggressive malignant tumor. Its high mortality rate prompts the urgent need for novel therapeutic agents. The aim of this study is to detect the expression of CRM1 in GC, which has not been reported to date. The expression of CRM1 in GC and adjacent noncancerous tissues (ANCT) of gastrectomy specimens from 120 GC patients was measured by immunohistochemistry. In addition, correlations between the CRM1 staining and the clinicopathologic features as well as survival were analyzed. Positive expression rates of CRM1 in GC and ANCT were 57.8 and 6.7%, respectively. High expression of CRM1 was significantly associated with increased serum level of carcinoma embryonic antigen (CEA, P = 0.02) but not associated with that of carbohydrate antigen 19-9 (P = 0.38). CRM1 levels were correlated with more advanced tumor stages (P = 0.01), positive Her2 status (P = 0.01), and distant metastasis (P = 0.02). Univariate analysis showed that CEA (P = 0.0076), TNM stage (P = 0.0001), metastasis (P = 0.027), and CRM1 expression (P = 0.0019) were significant risk factors affecting overall survival of GC patients. The multivariate analysis indicated that the CRM1 was an independent indicator for GC survival (P = 0.0048). The current results indicated that CRM1 expressed in a subpopulation of GC with aggressive behavior and could serve as a prognosis marker for poor outcome.
authors.affiliation: Department of Oncology, Affiliated Hospital of Medical College, Qingdao University, 16 Jiangsu Road, Qingdao, 266003, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Zhou
authors.forename: Wensheng
authors.initials: W
authors.lastname: Qiu
authors.forename: Ruyong
authors.initials: R
authors.lastname: Yao
authors.forename: Jinyu
authors.initials: J
authors.lastname: Xiang
authors.forename: Xiaoxiao
authors.initials: X
authors.lastname: Sun
authors.forename: Shihai
authors.initials: S
authors.lastname: Liu
authors.forename: Jing
authors.initials: J
authors.lastname: Lv
authors.forename: Lu
authors.initials: L
authors.lastname: Yue
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics; D018395:CA-19-9 Antigen / Q000235:genetics; D002277:Carcinoma / Q000235:genetics* / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D028884:Karyopherins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics*; D013274:Stomach Neoplasms / Q000235:genetics* / Q000473:pathology*; D000097606:Exportin 1 Protein
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D028884:Karyopherins; D018719:Erb-b2 Receptor Tyrosine Kinases; D018160:Receptors, Cytoplasmic and Nuclear; D000097606:Exportin 1 Protein
references.citation: Chin J Cancer Res. 2012 Dec;24(4):374-87
references.pmid: 23357869
references.citation: J Virol. 2005 Feb;79(4):2356-65
references.pmid: 15681436
references.citation: Commun Integr Biol. 2012 Sep 1;5(5):477-9
references.pmid: 23181164
references.citation: BMC Cancer. 2012 Dec 13;12:596
references.pmid: 23234464
references.citation: Microbes Infect. 2006 Mar;8(3):851-9
references.pmid: 16504563
references.citation: BMC Cancer. 2012 Jun 21;12:264
references.pmid: 22892134
references.citation: In Vivo. 2009 Mar-Apr;23(2):337-41
references.pmid: 19414423
references.citation: Zhonghua Wei Chang Wai Ke Za Zhi. 2012 Dec;15(12):1273-6
references.pmid: 23268276
references.citation: Cell Struct Funct. 2011;36(1):57-67
references.pmid: 21307607
references.citation: Neurosurgery. 2009 Jul;65(1):153-9; discussion 159-60
references.pmid: 19574837
references.citation: PLoS Negl Trop Dis. 2013;7(2):e2044
references.pmid: 23409202
references.citation: Cancer Biother Radiopharm. 2012 Sep;27(7):399-402
references.pmid: 22690887
references.citation: Oncol Rep. 2009 Jan;21(1):229-35
references.pmid: 19082467
references.citation: Cell Cycle. 2005 Nov;4(11):1510-4
references.pmid: 16294017
references.citation: Clin Invest Med. 2009 Dec 01;32(6):E315
references.pmid: 20003838
references.citation: Zhonghua Zhong Liu Za Zhi. 2007 Sep;29(9):657-61
references.pmid: 18246793
references.citation: Int J Mol Sci. 2012 Nov 19;13(11):15291-304
references.pmid: 23203126
references.citation: Gastric Cancer. 2014 Jan;17(1):43-53
references.pmid: 23389081
references.citation: Cancer. 2008 Apr 15;112(8):1733-43
references.pmid: 18306389
references.citation: Wiley Interdiscip Rev RNA. 2012 Jan-Feb;3(1):13-25
references.pmid: 21796793
references.citation: Int J Cancer. 2009 Apr 15;124(8):1829-40
references.pmid: 19117056
references.citation: Nucl Med Biol. 2009 Nov;36(8):883-94
references.pmid: 19875045
references.citation: ANZ J Surg. 2011 Sep;81(9):608-13
references.pmid: 22295383
references.citation: Int J Biol Markers. 2013 Jun 28;28(2):192-200
references.pmid: 23787496